Changes to the Roche Enlarged Corporate Executive Committee
27 Mai 2024 - 7:00AM
UK Regulatory
Changes to the Roche Enlarged Corporate Executive Committee
Basel, 27 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY)
announced today that James Sabry (1958), Head of Roche Pharma
Partnering, will be retiring after fourteen years with the
company.
James Sabry joined Genentech in 2010 as Head of Genentech
Partnering. In 2018, he became the Head of Pharma Partnering and a
member of the enlarged Corporate Executive Committee, based in
Basel, Switzerland. James Sabry completed an MD at Queen’s
University in Canada and his residency at Harvard Medical School,
and then completed a PhD in neuroscience at UCSF.
Boris Zaïtra (1972), currently Head of Group Business
Development, will be appointed Head of Corporate Business
Development effective 1 July 2024, a new role that will bring
together the Pharma Partnering and Group Business Development
functions. He will become a member of the enlarged Corporate
Executive Committee, reporting to Thomas Schinecker, Group CEO, and
will continue to be based in Basel.
Boris Zaïtra joined Roche in Basel in 2012 in his current role.
Prior to this, he had progressively expanding M&A leadership
responsibilities in multiple industries. He holds a Master of
Sciences from Ecole Polytechnique in France.
Roche’s CEO Thomas Schinecker: “James has been instrumental in
forging important deals for our Pharma R&D pipeline that have
led to numerous launches of new medicines. I am grateful for
James`s contributions to our company and for his dedication to our
purpose.” Schinecker further commented: “Leveraging external
innovation has always been and continues to be a critical part of
our business strategy. I am excited to have Boris Zaïtra take on
this new role. He brings an excellent combination of expertise in
M&A, experience in the industry, and leadership to the role.
”
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first
industrial manufacturers of branded medicines, Roche has grown into
the world’s largest biotechnology company and the global leader in
in-vitro diagnostics. The company pursues scientific excellence to
discover and develop medicines and diagnostics for improving and
saving the lives of people around the world. We are a pioneer in
personalised healthcare and want to further transform how
healthcare is delivered to have an even greater impact. To provide
the best care for each person we partner with many stakeholders and
combine our strengths in Diagnostics and Pharma with data insights
from the clinical practice.
In recognising our endeavour to pursue a long-term perspective
in all we do, Roche has been named one of the most sustainable
companies in the pharmaceuticals industry by the Dow Jones
Sustainability Indices for the fifteenth consecutive year. This
distinction also reflects our efforts to improve access to
healthcare together with local partners in every country we
work.
Genentech, in the United States, is a wholly owned member of the
Roche Group. Roche is the majority shareholder in Chugai
Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected
by law.
Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
Hans Trees, PhD
Phone: +41 79 407 72 58 |
Sileia
Urech
Phone: +41 79 935 81 48
|
Nathalie
Altermatt
Phone: +41 79 771 05 25
|
Simon
Goldsborough
Phone: +44 797 32 72 915
|
Karsten
Kleine
Phone: +41 79 461 86 83
|
Nina
Mählitz
Phone: +41 79 327 54 74 |
Kirti
Pandey
Phone: +49 172 6367262
|
Yvette
Petillon
Phone: +41 79 961 92 50 |
Dr.
Rebekka Schnell
Phone: +41 79 205 27 03 |
|
- 27052024_MR_Sabry Zaitra_en
Roche (LSE:0QQ6)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Roche (LSE:0QQ6)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024